Parthenolide, a Natural Inhibitor of Nuclear Factor-κB, Inhibits Lung Colonization of Murine Osteosarcoma Cells
Open Access
- 1 January 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (1) , 59-67
- https://doi.org/10.1158/1078-0432.ccr-06-1559
Abstract
Purpose: Renal cell carcinoma (RCC) accounts for 2% to 3% of all malignancies. It represents one of the most radiation- and chemotherapy-resistant tumors and surgical resections are only effective in organ-defined disease. However, RCC is an immunogenic tumor with response rates to immunotherapies between 10% and 20% of the treated patients. Due to the currently inefficient therapies and the low 5-year survival rates of RCC patients, novel diagnostic, prognostic, and therapeutic markers are urgently needed for this disease.Keywords
This publication has 32 references indexed in Scilit:
- Susceptibility of Cholangiocarcinoma Cells to Parthenolide-Induced ApoptosisCancer Research, 2005
- The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancerMolecular Cancer Therapeutics, 2005
- Rho/Rhotekin-mediated NF-κB activation confers resistance to apoptosisOncogene, 2004
- Microtubule-interfering activity of parthenolideChemico-Biological Interactions, 2004
- Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cellsCancer Letters, 2004
- Cross-talk between death and survival pathwaysCell Death & Differentiation, 2003
- VCP (p97) Regulates NFKB Signaling Pathway, Which Is Important for Metastasis of Osteosarcoma Cell LineJapanese Journal of Cancer Research, 2002
- Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolideOncogene, 2000
- OsteosarcomaEuropean Journal Of Cancer, 1997
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996